Saturday, October 1, 2022


Biotechnology News Magazine

HOOKIPA Executive Leadership Changes

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced several leadership changes as the company expands its clinical development and pipeline programs. All new appointments are effective July 1, 2022.

After five years, Igor Matushansky will step down as Chief Medical Officer (CMO) and Global Head of Research & Development, effective June 30, 2022. Matushansky will continue to contribute to HOOKIPA’s pipeline development as Chair of HOOKIPA’s Scientific Advisory Board.

Katia Schlienger has been promoted to Executive Vice President, Clinical Development. Schlienger was previously Senior Vice President, Head of Immuno-oncology. In her new role, Schlienger becomes a member of the Executive Team and will lead all clinical development programs for HOOKIPA globally, inclusive of immuno- oncology and infectious diseases.

Roman Necina, Chief Technology Officer, is appointed to the newly created role of Chief Development Officer (CDO). In addition to his current manufacturing responsibilities, he will be responsible for integrating Portfolio and Project Management, IT & Knowledge Management, and Operational Excellence across all line functions, with the goal of the accelerating the pipeline.

“We are grateful to Igor for his contributions in bringing our novel arenavirus technology from early preclinical to early clinical proof of concept. The Board and I look forward to continuing to work closely with him, benefiting from his expertise as Chair of our Scientific Advisory Board and providing counsel for HOOKIPA’s overall clinical strategy,” said Joern Aldag, Chief Executive Officer at HOOKIPA. “With Katia’s strong expertise in all phases of clinical development in oncology therapeutics and vaccines, she will seamlessly progress our clinical programs to the next level. Roman’s management skills will reinforce the integration of all areas of our company, strengthening our execution as we advance multiple assets through the clinic.”

“We have a very strong and experienced team in place that positions us well in the next phase of our organizational growth as we advance our arenavirus platform,” added Aldag.

About Katia Schlienger: Katia Schlienger, MD, PhD joined HOOKIPA as Senior Vice President, Head of Immuno-Oncology, in January 2021. She has had primary responsibility for the execution of the HB-200 therapeutic program for HPV16+ cancers, and its progression from Phase 1 to Phase 2. She was also instrumental in developing new clinical assets for prostate cancer and KRAS mutated tumors. Prior to HOOKIPA, Schlienger worked at Merck & Co., serving in roles of increasing responsibility across early and late-stage development in both oncology and vaccines. Earlier in her career, Schlienger was an Assistant Research Professor at University of Pennsylvania, where she worked in Carl June’s lab on immunotherapy for ovarian cancer and non-Hodgkin lymphoma. Schlienger received her MD in clinical pathology and PhD in microbiology with a focus on immunology and virology, from the School of Medicine Lariboisiere Saint-Louis and the Universite Denis Diderot in Paris, France, where her research included work on an HIV vaccine.

About Roman Necina: Roman Necina, PhD joined HOOKIPA in November 2019 as Chief Technology Officer, where he has led HOOKIPA’s manufacturing operations, including quality management and analytical and process development activities. At HOOKIPA, he has built a global strategic Contract Manufacturing Organization network and has been the driver of major efficiency improvements, de-risking arenavirus vector manufacturing. Prior to joining HOOKIPA, Necina was Senior Vice President and Chief Strategist at Takeda and a member of the company’s R&D Pharmaceutical Science Leadership Team. Previously, he held senior-level leadership positions at Baxter, Intercell and Boehringer Ingelheim, where he led plant expansions, established global manufacturing networks, and led change management processes. Roman obtained his PhD from the University of Natural Resources and Applied Life Sciences in Vienna.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine